Navigation Links
Vasomedical Again Named on Deloitte's Technology Fast 500 List

WESTBURY, N.Y., Nov. 13, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, today announced it has been named to the Deloitte's Technology Fast 500™ for the second consecutive year, with a ranking of 207 on the 2013 list, up from 443 on the 2012 list.

The Deloitte's Technology Fast 500 List is an annual ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.  The ranking is based on percentage annual revenue growth from 2008 to 2012, during which Vasomedical's total annual revenue increased by 501.2 percent.

"Vasomedical's success over the past several years is clearly a direct result of effective implementation of the strategy the Board of Directors put into place.  This includes diversifying our business, broadening our product offering and market presence through development and acquisition, as well as restructuring the leadership team with individuals with deep industry experience," commented Dr. Jun Ma, President and CEO of Vasomedical, Inc.

"We are pleased to be included on this list of prestigious companies, and this honor highlights the strides our Company has made in the right direction. We will continue to implement our growth strategy in the domestic and international medical marketplaces and continue to build value for our shareholders."

"The Deloitte's 2013 Technology Fast 500 companies are exemplary cases of those spurring growth in a tough market through innovation," said Eric Openshaw, vice chairman, Deloitte LLP and U.S. technology, media and telecommunications leader.  "This year's list is a who's who of companies behind the most exciting and innovative products and services in the technology space. We congratulate the Fast 500 companies and look forward to what they do next."

About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products.  The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at

Forward-Looking Statement
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contacts: 
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250 /  

Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273 / 

SOURCE Vasomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vasomedical to Report Third Quarter 2013 Results on November 14, 2013
2. Vasomedical Announces Financial Results for the Second Quarter of 2013
3. Vasomedical to Report Second Quarter 2013 Results on August 13, 2013
4. Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
5. Vasomedical Announces Financial Results for the First Quarter of 2013
6. Vasomedical to Report First Quarter 2013 Results on May 15, 2013
7. Randy Hill Appointed to Vasomedical Board of Directors
8. Vasomedical Announces Share Repurchase Program of up to $1.5 Million in Common Stock
9. Vasomedical Announces Financial Results for the Fourth Quarter and Year Ended 2012
10. Vasomedical to Report Fourth Quarter and Year End 2012 Results on April 1, 2013
11. Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at
Post Your Comments:
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):